The overall picture of the review encourages a study of the safety and efficacy of GLP-1 RA in cancer patients, especially in those at high or very high cardiovascular risk (i.e., history of CVD, T2DM, kidney disease, obesity) as a primary prevention strategy of HF and atherosclerosis. Here, GLP1R is linked to obesity disorder.